Eli Lilly says obesity pill helps maintain weight loss
Digest more
The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...
Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
A federal judge allowed some of Eli Lilly & Co.‘s claims to proceed that allege a Texas-based compounding pharmacy violated ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...
Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback